Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

This is a single-center, open, randomized parallel group design study to investigate the pharmacokinetic characteristics of Mitoxantrone Hydrochloride liposome injection in the treatment of relapsed/refractory lymphoma after the first administration, and the safety and efficacy.

Study Overview

• Status: Completed
• Conditions: Recurrent/Refractory Lymphoma
• Intervention / Treatment: Drug: Mitoxantrone Hydrochloride Liposome Injection

Detailed Description

The study was divided into three dosage groups: 12 mg/m2, 16 mg/m2 and 20 mg/m2,and three dosage groups were randomly divided into parallel groups.Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).

In the study before administration of the first cycle to cycle second will set up 16 blood points,to calculate the pharmacokinetic parameters of total mitoxantrone and free mitoxantrone after the first administration.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Guizhou
    • Guiyang, Guizhou, China, 550000
      • Guizhou Cancer Hospita

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria

Subjects must satisfy all the following conditions before enrollment:

1. Fully understand the clinical trail and sign the Informed Consent Form (ICF).
2. Ages range from 18 to 70 years (including 18 and 70 years), men and women are not limited.
3. Histopathologically and/or cytologically diagnosed relapsed/refractory lymphoma patients must undergo at least a first-line standard treatment for relapse or no remission and no better choice for advanced patients.
4. ECOG≤2.
5. The estimated survival time was at least 3 months.

6. The screening period of laboratory examination meet the following conditions, and 7 days before hematological evaluation during screening，subjects did not receive growth factor (long-acting granulocyte colony-stimulating factor needs 2 weeks interval), platelet or granulocyte transfusion:

   1. WBC≥3.5×109/L
   2. ANC≥1.5×109/L
   3. PLT≥75×109/L
   4. Hb≥90 g/L
   5. TBil≤1.5×ULN,If elevated bilirubin is caused by lymphoma invading the liver, the total bilirubin is allowed to be less than 3 x ULN.
   6. ALT/AST≤2.5×ULN，If the elevation is caused by lymphoma invading the liver, allow it to be less than 5 x ULN.
7. The toxicity of previous antineoplastic treatments was restored to ≤ 1 (except hair loss and pigmentation).
8. Female subjects were HCG negative in urine or blood (excluding menopause and hysterectomy)，men and women of childbearing age of the subjects take effective contraception during the experiment and 30 days of the end of last treatment.
9. Ability to visit on time and follow the procedures, limitations and requirements of the scheme.

Exclusion criteria

Subjects consistent with any one of the following conditions:

1. Subjects are consistent with one of the following conditions in the previous anti-tumor treatment history:

   1. Those receiving Mitoxantrone or Liposome-entrapped Mitoxantrone previously.
   2. Those receiving treatment of Adriamycin or other anthracyclines previously, with the total cumulative dose of > 360 mg/m2 (when converted to 1 mg Adriamycin, other anthracyclines shall be equivalent to 2 mg Epirubicin or 2 mg Pirarubicin or 2 mg Daunorubicin or 0.5 mg Idarubicin);
   3. Those receiving anti-tumor treatment (including chemotherapy, radiotherapy, hormone therapy or administration of TCM with anti-tumor activity) within 4 weeks prior to the first use of the study drug) or taking part in other clinical trials and accept medication in clinical trials;
   4. Those who have not yet fully recovered from previous surgical or invasive procedures.
2. Those with other malignant tumors previously or currently (except the non-melanoma skin basal cell carcinoma under effective control, breast/cervical carcinoma in situ, and other malignant tumors not treated but under effective control in the past five years).
3. Subjects with known or existing primary or metastatic central nervous system lymphoma or active brain metastasis

4. Cardiac dysfunction

   1. Male: QTc>450 ms, female: QTc>470 ms when ECG examination in the Research Center during the screening period;
   2. Clinically significant arrhythmias, including but not limited to complete left bundle branch block, Degree II atrioventricular block and PR interval > 250 ms;
   3. Any risk factor that might increase the QTc interval, e.g. hypokalaemia, inherited long-QT syndrome, with current administration of the drug for prolonging the QT interval or discontinuance for less than 15 days;
   4. Congestive heart failure of ≥Grade 2 in the New York Heart Association;
   5. Cardiac ejection fraction less than 50% or less than the lower limit of laboratory examination vale range of Research Center;
   6. Within six months prior to recruitment occurred myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, clinical history of severe pericardial disease, or electrocardiographic evidence of acute ischemia or abnormal active conduction system.
5. Subjects with known history of immediate or delayed hypersensitivity to the similar drug and excipient of the study drug.
6. Hepatitis B and hepatitis C active infection (HBsAg positive and HBsDNA more than 1000 copies / mL; HCV RNA more than 1000 copies / mL).
7. Human immunodeficiency virus (HIV) infection.
8. Uncontrollable systemic diseases (such as uncontrollable hypertension, diabetes, etc.).
9. Pregnant or lactating women.
10. Investigator believe that subjects have any conditions that are not suitable for participating in the experiment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Mitoxantrone Hydrochloride Liposome Injection（12 mg/m2）; itoxantrone Hydrochloride Liposome Injection（12 mg/m2）	Drug: Mitoxantrone Hydrochloride Liposome Injection; Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first). 5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.
EXPERIMENTAL: Mitoxantrone Hydrochloride Liposome Injection（16 mg/m2）; itoxantrone Hydrochloride Liposome Injection（16 mg/m2）	Drug: Mitoxantrone Hydrochloride Liposome Injection; Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first). 5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.
EXPERIMENTAL: Mitoxantrone Hydrochloride Liposome Injection（20mg/m2）; itoxantrone Hydrochloride Liposome Injection（20 mg/m2）	Drug: Mitoxantrone Hydrochloride Liposome Injection; Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first). 5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic indexes, Cmax Maximum concentration (Cmax)	aximum concentration (Cmax) of Mitoxantrone Hydrochloride Liposome	Up to 28 days
Pharmacokinetic indexes, Tmax	Time to Cmax (Tmax) of Mitoxantrone Hydrochloride Liposome	Up to 28 days
Pharmacokinetic indexes, Maximum concentration (Cmax,u)	Maximum concentration (Cmax,u) of Mitoxantrone Hydrochloride Liposome	Up to 28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
progression-free survival(PFS)	progression-free survival(PFS) of Mitoxantrone Hydrochloride Liposome	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first（assessed up to 100 months）

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with Adverse Events (AEs)	Adverse Events will be coded using Medical Dictionary for Regulatory Activities (MedDRA). An AE is any untoward medical occurrence in a patient or clinical study participant temporally associated with the use of study investigational product (IP), whether or not considered related to the study IP. "Adverse event" means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related	From the initiation of the first dose to 28 days after the last dose

Collaborators and Investigators

• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Investigators: Study Director: Yunhong Huang, Master, Cancer Hospital of Guizhou Province

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 29, 2019
• Primary Completion (ACTUAL): October 28, 2020
• Study Completion (ACTUAL): October 28, 2020

Study Registration Dates

• First Submitted: July 31, 2019
• First Submitted That Met QC Criteria: December 12, 2021
• First Posted (ACTUAL): December 30, 2021

Study Record Updates

• Last Update Posted (ACTUAL): December 30, 2021
• Last Update Submitted That Met QC Criteria: December 12, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; Lymphoma; Recurrence; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Mitoxantrone
• Other Study ID Numbers: PLM60-PK

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No